PTO/SB/08a (08-03.)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		
INFORMATION DIGGLOCULE	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Jon [OOBSON
(Not for submission under 37 CFR 1.99)	Art Unit		
(Examiner Name		
	Attorney Docket Number		13427.1001

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Date	Name of Pat of cited Docu	entee or Applicant ument	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wisl	n to ac	dd additional U.S. Pate							Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		Releva	,Columns,Lines where ant Passages or Relev s Appear	
	1	20060093611	A1	2006-0	5-04	Haj et al.				
	2	20040147015	A1	2004-0	7-29	El-Haj et al.				
If you wish	h to a	ı dd additional U.S. Pu b l	ished Ap	plication	n citatio	n information	please click the Add	d b utton	Add	
				FOREI	GN PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	•	Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	02051985	wo		A2	2002-07-04	Keele University		Page 4, Claims 1-13	
	2	0232397	wo		A2	2002-04-25	Virginia Commonw University Intellecti Prop	ıal	Page 42, Examples, Claims	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor	lon DOBSON	
Art Unit		
Examiner Name		
Attorney Docket Numbe	13427.1001	

	3	2004000369	wo	A2	2003-12-31	Keele University	whole document			
If you wis	h to a	 dd additional Foreig	l n Patent Docume	nt citatio	 n information p	 lease click the Add butt	on Add			
			NON-PAT	ENT LIT	ERATURE DO	CUMENTS	Remove			
Examiner Initials*	Cite No	[(book magazine journal serial symposium catalog etc) date pages(s) volume-issue number(s)								
	1	LEWIN, M., ET AL. "Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells," Nature Biotechnology, Vol., 18, No. 4, pp. 410-414 (April 2000)								
	2	CARTMELL, S.H., ET AL. "Development of magnetic particle techniques for long-term culture of bone cells with intermittent mechanical activation," IEEE Transactions on Nanobioscience, pp. 92-97 (June 2002)								
	3	FROHLICH, M.W., ET AL. "Ex Vivo Activation and Expansion of T Cells from the Peripheral Blood of Multiple Myeloma Patients Using the Xcellerate™ Process," Blood, Vol. 100, No. 11, Abstract No. 5259 (16 Nov. 2002)								
If you wis	h to a	dd additional non-pa	atent literature doc	ument c	itation informat	ion please click the Add	button Add			
			E	XAMINE	ER SIGNATUR	RE				
Examiner Signature						Date Considered				
			•			formance with MPEP 60 with next communication	•			
Standard ST ⁴ Kind of doo	r.3). ³ F cument	or Japanese patent doc	uments, the indication	of the year	of the reign of the	Emperor must precede the s	nent, by the two-letter code (W erial number of the patent doo dicant is to place a check man	cument.		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor	Jon DOBSON	
Art Unit		
Examiner Name		
Attorney Docket Numb	er 13427.1001	

		CE	RTIFICATION	STATEMENT		
Plea	ase see 37 CFR 1	.97 and 1.98 to make the appro	opriate selecti	on(s):		
	from a foreign p		foreign applica		first cited in any communication months prior to the filing of the	
OR	1					
	foreign patent o after making rea any individual d	ffice in a counterpart foreign a sonable inquiry, no item of info	application, an ormation conta	d, to the knowledge of th ined in the information di	cited in a communication from a ne person signing the certification sclosure statement was known to ling of the information disclosure	
	See attached ce	rtification statement.				
	Fee set forth in 3	37 CFR 1.17 (p) has been subn	nitted herewith			
V	None		SIGNAT		40. 51	
	ignature of the ap of the signature		uirea in accord	nance with CFK 1.33, 10.	18. Please see CFR 1.4(d) for the	
Sigr	nature	/janet sleath/		Date (YYYY-MM-DD)	2006-06-16	-
Name/Print Janet Sleath				Registration Number	37007	-

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a
 court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement
 negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.